Niraparib

SKU: orb1304399

Description

Niraparib (MK-4827) is a potent and selective PARP1/2 inhibitor (IC50=3.8/2.1 nM) that impedes DNA repair, leading to apoptosis. It is widely used in oncology research, demonstrating antitumor efficacy in both cellular assays and in vivo models of BRCA-mutated and homologous recombination-deficient cancers.

Research Area

Cell Biology, Epigenetics & Chromatin, Molecular Biology

Key Properties

• CAS Number: 1038915-60-4
• MW: 320.39
• Purity: 99.85%
• Formula: C₁₉H₂₀N₄O
• SMILES: C(N)(=O)C=1C=2C(=CN(N2)C3=CC=C(C=C3)[C@@H]4CCCNC4)C=CC1
• Target: PARP,Apoptosis
• Solubility: DMSO:65.63 mg/mL (204.84 mM);Ethanol:60 mg/mL (187.27 mM);H2O:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:6 mg/mL (18.73 mM)

Bioactivity

• Target IC50:
  PARP4:330 nM|tankyrase 1:570 nM|PARP2:2.1 nM|PARP1:3.8 nM|PARP3:1300 nM
• In Vivo:
  METHODS: To detect anti-tumor activity in vivo, Niraparib (25 mg/kg, administered orally four times per week) and PD-L1 (10 mg/kg, administered intraperitoneally twice per week) were administered to C57BL/6 mice bearing ovarian cancer tumor ID8 for eight weeks. RESULTS: Niraparib upregulated PD-L1 expression in ovarian tumors in vivo and synergized with PD-L1 blockade. METHODS: To detect anti-tumor activity in vivo, Niraparib (50 mg/kg, 0.5% methylcellulose) was administered by gavage to C57BL/6 mice bearing intracranial human-derived TNBC cell lines SUM149, MDA-MB-231Br, or MDA-MB-436 once daily for two weeks. RESULTS: In the BRCA mutant MDA-MB-436 model, Niraparib increased median survival and decreased tumor load. However, it did not increase in the BRCA mutant SUM149 or BRCA wild-type MDA-MB-231Br models, despite high concentrations in intracranial tumors.
• In Vitro:
  METHODS: The PDAC cell lines MIA-PaCa-2, PANC-1, Capan-1 and the OvCa cell lines OVCAR8, PEO1 were treated with Niraparib (0.1-200 µM) for 48 h, and the cells were assayed for viability using the CellTiter-Glo Luminescent Cell Viability Assay. RESULTS: The IC50 of Niraparib on MIA-PaCa-2, PANC-1, Capan-1, OVCAR8, and PEO1 cells were 26 µm, 50 µm, 15 µM, 20 µM, and 28 µM, respectively. . METHODS: Ovarian cancer cells SKOV3 and UWB1.289 were treated with Niraparib (0.5-15 µM) for 48 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: Niraparib upregulated the expression of PD-L1 in SKOV3 and UWB1.289 cells.
• Cell Research:
  Proliferation assays were conducted in 96-well black viewplates, and 300 cells/well (250 cell/well for BRCA-1 wt) in culture medium, 190 μL/well (DMEM containing 10% FCS, 0.1 mg/mL penicillin-streptomycin, and 2 mM L-glutamine), were plated and incubated for 4 h at 37℃ under 5% CO2 atmosphere. Inhibitors were then added with serial dilutions, 10 μL/well to obtain the desired final compound concentration in 0.5% DMSO. The cells were then incubated for 7 days at 37℃ in 5% CO2 after which time viability was assessed. Briefly, with CellTiter-Blue solution prediluted 1:10 in medium, 100 μL/well was added and the cells left for 45 min at 37℃ under 5% CO2 and then a further 15 min at room temperature in the dark. The number of living cells was determined by reading the plate at fluorimeter, excitation at 550 nm and emission at 590 nm. Cell growth was expressed as the percentage growth with respect to vehicle treated cells. The concentration required to inhibit cell growth by 50% (CC50) was determined.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

breast, damage, DNA, bioavailable, cancer, Apoptosis, anti-tumor, Inhibitor, MK-4827, MK4827, MK 4827, PARP2, PARP3, PARP1, PARP, ovarian, poly ADP ribose polymerase, Niraparib, orally, inhibit, lung, TANK-1, V-PARP

Compound Identifiers

PubChem CID

24958200